Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Infinity Pharmaceuti (INFI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 83,681
  • Shares Outstanding, K 56,926
  • Annual Sales, $ 22,150 K
  • Annual Income, $ -11,250 K
  • 60-Month Beta 2.10
  • Price/Sales 3.80
  • Price/Cash Flow N/A
  • Price/Book 2.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.16
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.18
  • Prior Year -0.12
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.40 +5.00%
on 05/14/19
1.78 -17.31%
on 05/06/19
-0.09 (-5.77%)
since 04/17/19
3-Month
1.30 +13.08%
on 02/21/19
1.95 -24.62%
on 03/14/19
+0.08 (+5.76%)
since 02/15/19
52-Week
1.00 +47.00%
on 12/26/18
2.92 -49.66%
on 10/02/18
-0.52 (-26.13%)
since 05/17/18

Most Recent Stories

More News
Infinity Pharmaceuticals To Present At B. Riley FBR Institutional Investor Conference

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins, Infinity Pharmaceutical's Chief Executive Officer, will present at the B. Riley FBR Institutional Investor Conference...

INFI : 1.47 (-0.68%)
Infinity (INFI) Earnings and Sales Miss Estimates in Q1

Infinity (INFI) posts wider-than-expected loss in the first quarter of 2019. Sales miss estimates in the quarter.

RCUS : 9.46 (-4.73%)
INFI : 1.47 (-0.68%)
RHHBY : 32.8400 (+0.71%)
BMY : 46.85 (-0.57%)
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Lags Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -380.00% and -78.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

INFI : 1.47 (-0.68%)
Infinity: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Tuesday reported a loss of $13.7 million in its first quarter.

INFI : 1.47 (-0.68%)
Infinity Pharmaceuticals Provides Company Update and First Quarter 2019 Financial Results

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2019 financial results and provided an update on the company, including its progress in expanding the breadth and depth of...

INFI : 1.47 (-0.68%)
Infinity Announces the Date of Its First Quarter 2019 Financial Results Conference Call and Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, May 7, at 4:30 p.m. ET to review its first quarter 2019 financial results and provide an update on the company.

INFI : 1.47 (-0.68%)
Infinity (INFI) Down 10% Since Last Earnings Report: Can It Rebound?

Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INFI : 1.47 (-0.68%)
Beat Q1 Earnings Woes With These Sector ETFs & Stocks

The Q1 earnings picture looks bleak with projected growth turning negative for the first time since the second quarter of 2016.

XLU : 58.78 (+0.51%)
LMT : 337.99 (-0.41%)
XLV : 88.44 (-0.21%)
ITA : 205.70 (-0.77%)
OKE : 68.17 (+0.10%)
INFI : 1.47 (-0.68%)
KSS : 63.60 (-0.27%)
XRT : 42.65 (-0.72%)
Beat Q1 Earnings Woes With These Sector ETFs & Stocks

The Q1 earnings picture looks bleak with projected growth turning negative for the first time since the second quarter of 2016.

XLU : 58.78 (+0.51%)
LMT : 337.99 (-0.41%)
XLV : 88.44 (-0.21%)
ITA : 205.70 (-0.77%)
OKE : 68.17 (+0.10%)
INFI : 1.47 (-0.68%)
KSS : 63.60 (-0.27%)
XRT : 42.65 (-0.72%)
Detailed Research: Economic Perspectives on KB Home, Fitbit, Adamas Pharmaceuticals, Ballard Power, Infinity Pharmaceuticals, and Credit Acceptance -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of KB Home (NYSE:KBH), Fitbit,...

KBH : 26.95 (-1.53%)
FIT : 4.91 (-2.58%)
CACC : 471.49 (-1.08%)
ADMS : 5.73 (-3.86%)
BLDP : 3.86 (unch)
INFI : 1.47 (-0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade INFI with:

Business Summary

Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

See More

Key Turning Points

2nd Resistance Point 1.52
1st Resistance Point 1.49
Last Price 1.47
1st Support Level 1.44
2nd Support Level 1.42

See More

52-Week High 2.92
Fibonacci 61.8% 2.19
Fibonacci 50% 1.96
Fibonacci 38.2% 1.73
Last Price 1.47
52-Week Low 1.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar